Novartis CEO on Sandoz Revamp, Covid-19 Vaccines

The transcript discusses Novartis's market recovery, challenges in Q1, and strategies for Sandoz's growth, focusing on biosimilars. It highlights Novartis's efforts in COVID-19 through partnerships and manufacturing, and outlines their hybrid work model. The company is also involved in RNA technology, with plans for future growth.

How does Novartis's return to office plan reflect its commitment to a hybrid working environment?

In what ways does Novartis aim to attract and access talent through its working model?

What is the significance of Novartis's investment in RNA technology?